JOP20190218A1 - مركبات ثنائية النيوكليوتيدات حلقية معدلة - Google Patents

مركبات ثنائية النيوكليوتيدات حلقية معدلة

Info

Publication number
JOP20190218A1
JOP20190218A1 JOP/2019/0218A JOP20190218A JOP20190218A1 JO P20190218 A1 JOP20190218 A1 JO P20190218A1 JO P20190218 A JOP20190218 A JO P20190218A JO P20190218 A1 JOP20190218 A1 JO P20190218A1
Authority
JO
Jordan
Prior art keywords
cyclic dinucleotide
modified cyclic
dinucleotide compounds
compounds
modified
Prior art date
Application number
JOP/2019/0218A
Other languages
English (en)
Inventor
Christian Andreas Kuttruff
Sebastian Carotta
Thorsten Oost
Martin Fleck
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20190218A1 publication Critical patent/JOP20190218A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)

Abstract

مركبات الصيغة (I) حيث يتم تعريف القاعدة 1 والقاعدة 2 بكما في عنصر الحماية 1 بأنهم معدلات STING.
JOP/2019/0218A 2017-03-22 2017-06-16 مركبات ثنائية النيوكليوتيدات حلقية معدلة JOP20190218A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17162392 2017-03-22

Publications (1)

Publication Number Publication Date
JOP20190218A1 true JOP20190218A1 (ar) 2019-09-22

Family

ID=58412904

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0218A JOP20190218A1 (ar) 2017-03-22 2017-06-16 مركبات ثنائية النيوكليوتيدات حلقية معدلة

Country Status (20)

Country Link
US (1) US10392419B2 (ar)
EP (1) EP3601313B1 (ar)
JP (2) JP6742534B2 (ar)
KR (1) KR20190130612A (ar)
CN (1) CN110382515B (ar)
AR (1) AR111247A1 (ar)
AU (1) AU2018239468A1 (ar)
BR (1) BR112019017812A2 (ar)
CA (1) CA3056008A1 (ar)
CL (1) CL2019002590A1 (ar)
CO (1) CO2019010023A2 (ar)
EA (1) EA201992209A1 (ar)
IL (1) IL268799A (ar)
JO (1) JOP20190218A1 (ar)
MX (1) MX2019011281A (ar)
PE (1) PE20191556A1 (ar)
PH (1) PH12019502155A1 (ar)
SG (1) SG11201908567UA (ar)
TW (1) TW201842919A (ar)
WO (1) WO2018172206A1 (ar)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
KR102722183B1 (ko) * 2016-06-24 2024-10-24 바이오젠 엠에이 인코포레이티드 캡핑 단계 없이 티올화된 올리고뉴클레오타이드의 합성
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
PH12020550585A1 (en) 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US20210024567A1 (en) * 2018-03-27 2021-01-28 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020117623A1 (en) * 2018-12-07 2020-06-11 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3891166A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US20220033431A1 (en) * 2018-12-07 2022-02-03 Merck Sharp & Dohme Corp. Cyclic Di-Nucleotide Compounds as STING Agonists
WO2020210317A1 (en) 2019-04-10 2020-10-15 Wake Forest University Health Sciences Immunotherapeutic nanoparticles and methods relating thereto
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN114127082A (zh) 2019-05-09 2022-03-01 阿里戈斯治疗公司 作为sting调节剂的经修饰的环状二核苷化合物
TWI925817B (zh) 2019-05-10 2026-05-21 日商武田藥品工業股份有限公司 抗體藥物結合物
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CA3157192A1 (en) * 2019-10-07 2021-04-15 The General Hospital Corporation Compositions and methods for pulmonary surfactant-biomimetic nanoparticles
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
SG11201502796RA (en) * 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) * 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
EP3507367A4 (en) * 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة

Also Published As

Publication number Publication date
EP3601313A1 (en) 2020-02-05
EP3601313B1 (en) 2021-03-10
AR111247A1 (es) 2019-06-19
CN110382515B (zh) 2023-03-03
KR20190130612A (ko) 2019-11-22
JP2020203887A (ja) 2020-12-24
IL268799A (en) 2019-10-31
SG11201908567UA (en) 2019-10-30
PH12019502155A1 (en) 2020-07-06
US20180273578A1 (en) 2018-09-27
CL2019002590A1 (es) 2020-01-24
CA3056008A1 (en) 2018-09-27
US10392419B2 (en) 2019-08-27
PE20191556A1 (es) 2019-10-24
CN110382515A (zh) 2019-10-25
JP2020514389A (ja) 2020-05-21
JP6742534B2 (ja) 2020-08-19
MX2019011281A (es) 2019-11-01
BR112019017812A2 (pt) 2020-03-31
EA201992209A1 (ru) 2020-03-16
TW201842919A (zh) 2018-12-16
CO2019010023A2 (es) 2019-09-30
AU2018239468A1 (en) 2019-09-12
WO2018172206A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
PH12019502155A1 (en) Modified cyclic dinucleotide compounds
PH12019500706A1 (en) Cyclic dinucleotide compounds
PH12019502870A1 (en) Small molecule modulators of human sting
ZA201805009B (en) Stable inoculant compositions and methods for producing same
MX2020009347A (es) Picolinamidas como fungicidas.
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12019502646A1 (en) Pyrazole magl inhibitors
ZA201507627B (en) P2x7 modulators
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
GB2547402A (en) Prevention and treatment of microbial infections
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
DOP2013000016A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
EP4700174A3 (en) High wet fast disperse dye mixtures
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
MX2017008423A (es) Formulaciones transdérmicas.
PH12018502556A1 (en) Cosmetic base including amide alcohol, and cosmetic
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
NZ735398A (en) Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors
MX375896B (es) Agentes anticancerosos y sus preparaciones.
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
EP4566666A3 (en) Compositions and methods for modulating factor ix function
SG10201808383UA (en) Cyclic apelin analogs
MY196560A (en) Novel Pyrrolidine Derivatives